CHRO — Channel Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $7.69m
- $9.36m
Annual income statement for Channel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.2 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.55 | 0.839 | 2.32 | 6.86 | 7.21 |
| Operating Profit | -1.35 | -0.839 | -2.32 | -6.86 | -7.21 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.661 | -0.595 | -2.46 | -7.38 | -7.96 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.661 | -0.595 | -2.46 | -7.38 | -7.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.661 | -0.595 | -2.46 | -7.38 | -7.96 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.661 | -0.595 | -2.46 | -7.38 | -7.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.115 | -0.103 | -0.426 | -1.28 | -1.49 |
| Dividends per Share |